Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Appointment to the Board

14 Oct 2019 07:00

RNS Number : 6157P
NetScientific PLC
14 October 2019
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Appointment to the Board

 

London, UK - 14 October 2019 - NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, is pleased to announce that Dr. Ilian Iliev will join the Board with immediate effect as a non-executive director.

 

Ilian founded EMV Capital Limited, a London-based international VC investor, focused on B2B companies in industrial high-tech, energy, smart cities, transportation and healthtech. The firm's investment model is to de-risk technologically complex investments through industrial partnerships with some of the world's leading corporations, as well as attracting financial investors to its portfolio companies. EMV Capital Limited is a spin-out from EcoMachines Ventures Limited, which was founded by Ilian in 2013.

 

Ilian holds a PhD from Cambridge University's Judge Business School, MCom in Economics and BA in Politics, Economics and International Relations from the University of Witwatersrand. He is also an Associate Fellow at Chatham House, focused on energy and resource efficiency.

 

Dr. Ilian Petkov Iliev (aged 44) currently holds or has held in the past 5 years the following directorships and partnerships:

 

Current directorships

Past Directorships & Partnerships

EMV Capital Limited

EcoMachines Ventures Limited

Q-Bot Limited

Autorose Limited

Sofant Technologies Limited

Power Drive Efficiency Limited

Pointgrab, Inc. (Israel)

Recycling Technologies Limited

Wanda Health, Inc. (USA)

Pulsar Capital Solutions Limited

Vortex Biosciences, Inc. (USA)

Rotary EcoMachines Limited

Cambridge Intellectual Property Limited

DiagnovIS Limited

Satipimpex (South Africa)

 

Zoom Growth Investments Limited

 

London Innovation Partners Limited

Deeptech Growth Investments Limited

Futura Messis Group Limited

BusiPro O.O.D. (Bulgaria)

 

 

In addition, Dr Iliev was a director of Stratpol Advisory Services Limited, which entered into a voluntary arrangement with its creditors in February 2010. The deficit to creditors was £22,231.98.

 

No further disclosure is required under Paragraph (g) to Schedule Two of the AIM Rules for Companies.

 

Commenting on the appointment, Sir Richard Sykes, Executive Chairman of NetScientific, said:

 

"We welcome Ilian to the board of NetScientific and look forward to his contribution to the Board."

 

For more information, please contact:

 

  NetScientific

Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800

 

 

WHIreland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel

Tel: +44 (0)20 7220 1666

 

 

MO PR ADVISORY (Press Contact)

Mo Noonan

Tel: +44 (0)78 7644 4977

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

 

For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUARKRKAARARA
Date   Source Headline
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.